Complete Guide to Mirvetuximab Soravtansine (ELAHERE) Pharmacokinetics
Overview
Mirvetuximab Soravtansine (ELAHERE) is a Antibody-Drug Conjugate (ADC) used in the Oncology / Ovarian Cancer therapeutic area. It is indicated for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload. Population PK simulator for mirvetuximab soravtansine (ELAHERE, IMGN853) — FRα-targeted ADC with DM4 maytansinoid payload for platinum-resistant ovarian cancer. Two-compartment ADC model with albumin covariate on clearance and AIBW-based dosing. The first ADC to show OS benefit vs chemotherapy in a solid tumor (MIRASOL trial). Based on Choudhry et al. CPT 2023 and FDA Clinical Pharmacology Review.
Mechanism of Action
Mirvetuximab Soravtansine (ELAHERE) exerts its pharmacological effect by targeting FRα (Folate Receptor Alpha, FOLR1). As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Population PK (2-CMT ADC + 1-CMT DM4 Payload) models for Mirvetuximab Soravtansine (ELAHERE):
| Parameter | Value |
|---|---|
| k12 | 0.22 |
| k21 | 0.3 |
| ADC CL | 0.65 |
| DM4 Vd | 420 |
| Standard Dose | 6 |
| DM4 Payload CL | 38 |
| ADC V1 (Central) | 3.8 |
| ADC V2 (Peripheral) | 2.1 |
| Albumin Exponent on CL | 0.45 |
| Payload Release Rate (kr) | 0.008 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Mirvetuximab Soravtansine (ELAHERE) is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology / Ovarian Cancer therapeutic area, for the treatment of FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload, understanding the pharmacokinetics of Mirvetuximab Soravtansine (ELAHERE) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Mirvetuximab Soravtansine (ELAHERE) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Mirvetuximab Soravtansine (ELAHERE) PK Simulator
Explore Mirvetuximab Soravtansine (ELAHERE) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Mirvetuximab Soravtansine (ELAHERE)?
The elimination half-life of Mirvetuximab Soravtansine (ELAHERE) depends on patient-specific factors. Use our interactive Mirvetuximab Soravtansine (ELAHERE) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Mirvetuximab Soravtansine (ELAHERE) administered?
Mirvetuximab Soravtansine (ELAHERE) is administered via the IV Infusion route. It is indicated for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Mirvetuximab Soravtansine (ELAHERE)?
Key pharmacokinetic parameters for Mirvetuximab Soravtansine (ELAHERE) include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Mirvetuximab Soravtansine (ELAHERE) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Mirvetuximab Soravtansine (ELAHERE) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.